ArticleVirchows Archiv : an international journal of pathology2026
Idylla™ POLE-POLD1 mutation assay for molecular characterization and risk stratification of endometrial cancers: a retrospective multicenter validation study.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinoma (EC) is a common gynecological cancer with rising incidence driven by obesity and aging populations. Accurate and timely molecular classification is critical for guiding personalized oncology treatment, especially in early-stage high-grade endometrioid carcinoma. Here we present a large scale, retrospective multicenter validation of a novel POLE-POLD1 mutation assay for use in molecular characterization of EC. We evaluated the analytical performance and robustness of the novel Idylla™ POLE-POLD1 Mutation Assay, a cartridge-based PCR platform optimized for FFPE tissue. Performance comparators were established NGS reference methods. Overall, 544 formalin-fixed, paraffin embedded (FFPE) EC cases from diagnostic pathology of ten centers in Europe and North America were included. Of 544 samples, 520 revealed POLE-POLD1 test and comparator results, yielding an overall concordance of 97% (PPA of 0.96 and NPA of 0.98). Discordance was limited to a small number of variants and was often associated with low input material or the detection of multiple concurrent variants. The assay demonstrated robust performance across variable FFPE slice thickness (4-10 μm), number of Sects. (1-6), and tumor cell percentage (from 10% to 100%), with an assay invalid rate of only 2.76%. Moreover, the Idylla™ platform offers rapid results (~ 2 h) with minimal workflow complexity. The Idylla™ POLE-POLD1 Mutation Assay is a reliable and rapid diagnostic assay for clinically relevant molecular classification of EC, demonstrating high concordance with NGS and robust performance under routine pathology conditions. Whereas NGS provides comprehensive genomic profiling, including rare variants of unknown pathogenic significance, the Idylla™ assay targets treatment relevant pathogenic variants with rapid turnaround time, supporting timely, individualized treatment decisions.
Indexed as
Identifiers
42579138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.